Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Systematic assessment for potential endogenous normalizers for microRNA analysis in fecal samples.

Scientific reports·2026

Same author

Rational design of a modular mRNA vaccine platform for rapid adaptation to SARS-CoV-2 variants.

Scientific reports·2026

Same author

Astrocytic-OTUD7B ameliorates murine experimental autoimmune encephalomyelitis by stabilizing glial fibrillary acidic protein and preventing inflammation.

Nature communications·2025

Same author

Atypical Mitochondrial Phenotype of Colonic CD4+ and CD8+ T Cells During Experimental Chronic Colitis.

Biomedicines·2025

Same author

Epigenetic changes and serotype-specific responses of alveolar type II epithelial cells to Streptococcus pneumoniae in resolving influenza A virus infection.

Cell communication and signaling : CCS·2025

Same author

<i>In vivo</i> RNAi screen and validation reveals Ngp, Hba-a1, and S100a8 as novel inhibitory targets on T lymphocytes in liver cancer.

Frontiers in immunology·2025

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Association between PPARalpha gene polymorphisms and myocardial infarction.

Wibke Reinhard¹, Klaus Stark, Kamil Sedlacek

¹Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Regensburg, Germany.

Clinical Science (London, England : 1979)

|March 14, 2008

Summary

This summary is machine-generated.

Genetic variations in the peroxisome-proliferator-activated receptor alpha (PPARalpha) gene are linked to myocardial infarction risk. Common PPARalpha gene variations may influence heart attack susceptibility in European populations.

Related Experiment Videos

Last Updated: Jul 6, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

Genetics
Cardiovascular Disease Research
Molecular Biology

Background:

Peroxisome-proliferator-activated receptor alpha (PPARalpha) regulates lipid metabolism, tissue homeostasis, and inflammation.
Consistent rodent and human studies suggest a link between PPARalpha function and cardiovascular disease.
PPARalpha is a candidate gene for coronary artery disease.

Purpose of the Study:

To comprehensively evaluate common genetic variations within the PPARalpha gene.
To assess the association between PPARalpha gene variations and myocardial infarction risk.

Main Methods:

Characterized linkage disequilibrium within the PPARalpha gene using single nucleotide polymorphisms (SNPs).
Analyzed association of SNPs and haplotypes with myocardial infarction in initial and independent case-control cohorts.
Utilized data from the Regensburg Myocardial Infarction Family Study and WHO MONICA Augsburg project.

Main Results:

A single SNP (rs135551) showed significant association with myocardial infarction (OR=0.74, P=0.012).
A protective three-marker haplotype demonstrated an association trend (OR=0.76, P=0.067).
Results were confirmed in an independent cohort, with rs135551 (OR=0.87, P=0.046) and the haplotype (OR=0.80, P=0.034) showing significant associations.

Conclusions:

Common variations in the PPARalpha gene are associated with myocardial infarction risk.
Evidence suggests PPARalpha gene variations influence heart attack susceptibility in European populations.
Further research into PPARalpha's role in cardiovascular disease is warranted.